Armata Pharmaceuticals received FDA Breakthrough Therapy designation for AP-SA02, an intravenous multi-phage treatment targeting complicated Staphylococcus aureus bacteremia, including MRSA and MSSA. This designation, alongside Fast Track and QIDP statuses, highlights AP-SA02's potential to improve outcomes over current therapies, supported by positive Phase 2 clinical data showing higher cure rates and no relapse in treated patients. Armata plans to start a Phase 3 superiority trial in late 2026, aiming to bring this novel antibacterial therapy to market faster for serious bloodstream infections with high relapse and mortality rates.
Alphabet is investing heavily in nuclear power contracts to power its AI data centers, suspending share buybacks, and doubling its debt load to support massive capital expenditures. This move reflects confidence in sustained AI demand, backed by stro...
Acurx Pharmaceuticals presented a study showing ibezapolstat (IBZ) outperforms vancomycin and fidaxomicin in killing Clostridioides difficile and vancomycin-resistant Enterococcus (VRE) in lab tests. IBZ maintained strong bactericidal activity even i...
NVIDIA and Palantir both reported strong quarterly results, highlighting unstoppable AI growth. NVIDIA focuses on the physical infrastructure powering AI models, with revenue up 106% and a strong data center segment. Palantir excels in software that ...
The upcoming US Senate vote on the CLARITY Act, which aims to clarify regulatory authority over cryptocurrencies, threatens a $9.46 million short squeeze in XRP if the price rises just 5% to $1.4644. Currently trading around $1.40, XRP is near a tech...
Intel reported its strongest revenue growth in over 15 years with Q2 2026 revenue hitting $16.128 billion, driven by a 59% surge in Data Center and AI revenue. Shares have tripled in the past year, rising 318%, but momentum is slowing due to ongoing ...
